Chemo-induced biology of PD-L1 and in vivo combination immune therapy for ovarian cancer

被引：0
|
作者：
Grabosch, Shannon
Zeng, Feitianzhi
Zhang, Lixin
Ma, Tianzhou
Tseng, George
Edwards, Robert P.
Vlad, Anda M.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-3208
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3208
引用
收藏
页数：4
相关论文
共 50 条
  • [41] PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
    Stein, Alexander
    Simnica, Donjete
    Schultheiss, Christoph
    Scholz, Rebekka
    Tintelnot, Joseph
    Goekkurt, Eray
    von Wenserski, Lisa
    Willscher, Edith
    Paschold, Lisa
    Sauer, Markus
    Lorenzen, Sylvie
    Riera-Knorrenschild, Jorge
    Depenbusch, Reinhard
    Ettrich, Thomas J.
    Doerfel, Steffen
    Al-Batran, Salah-Eddin
    Karthaus, Meinolf
    Pelzer, Uwe
    Waberer, Lisa
    Hinke, Axel
    Bauer, Marcus
    Massa, Chiara
    Seliger, Barbara
    Wickenhauser, Claudia
    Bokemeyer, Carsten
    Hegewisch-Becker, Susanna
    Binder, Mascha
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
  • [42] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
    Akintunde Akinleye
    Zoaib Rasool
    Journal of Hematology & Oncology, 12
  • [43] Immune Escape Mediated by Exosomal PD-L1 in Cancer
    Lawler, Sean E.
    Nowicki, Michal O.
    Ricklefs, Franz L.
    Chiocca, E. Antonio
    ADVANCED BIOSYSTEMS, 2020, 4 (12)
  • [44] A narrative review of combination therapy of PD-1/PD-L1 blockade with standard approaches for the treatment of breast cancer: clinical application and immune mechanism
    Zhu, Wang-Yu
    Jin, Xiao-Yan
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (09) : 10075 - 10082
  • [45] Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer
    Xue, Chunyan
    Zhu, Dawei
    Chen, Lujun
    Xu, Yun
    Xu, Bin
    Zhang, Dachuan
    Jiang, Jingting
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (01) : 111 - 119
  • [46] PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
    Katerina Ancevski Hunter
    Mark A. Socinski
    Liza C. Villaruz
    Molecular Diagnosis & Therapy, 2018, 22 : 1 - 10
  • [47] LDHB Mediates Histone Lactylation to Activate PD-L1 and Promote Ovarian Cancer Immune Escape
    Hu, Xuemei
    Huang, Zhenqiang
    Li, Lingyun
    CANCER INVESTIGATION, 2025, 43 (01) : 70 - 79
  • [48] Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?
    Gaillard, S. L.
    Coleman, R. L.
    ANNALS OF ONCOLOGY, 2019, 30 (07) : 1025 - 1028
  • [49] Interferon-γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer
    Imai, Yushi
    Chiba, Tetsuhiro
    Kondo, Takayuki
    Kanzaki, Hiroaki
    Kanayama, Kengo
    Ao, Junjie
    Kojima, Ryuta
    Kusakabe, Yuko
    Nakamura, Masato
    Saito, Tomoko
    Nakagawa, Ryo
    Suzuki, Eiichiro
    Nakamoto, Shingo
    Muroyama, Ryosuke
    Tawada, Akinobu
    Matsumura, Tomoaki
    Nakagawa, Tomoo
    Kato, Jun
    Kotani, Ai
    Matsubara, Hisahiro
    Kato, Naoya
    ONCOLOGY LETTERS, 2020, 20 (03) : 2161 - 2168
  • [50] PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
    Hunter, Katerina Ancevski
    Socinski, Mark A.
    Villaruz, Liza C.
    MOLECULAR DIAGNOSIS & THERAPY, 2018, 22 (01) : 1 - 10
12345